OpenAI-backed biotech firm Chai Discovery raises $130M Series B at $1.3B valuation | TechCrunch
Chai Discovery raised a $130 million Series B at a $1.3 billion valuation to advance AI-driven molecular design; Chai 2 improves de novo antibody design.
MIT drug hunters are using AI to design completely new antibiotics
AI-generated de novo molecular design produced millions of novel compounds and yielded AI-designed antibiotics that cleared drug-resistant infections in mice.
Saudi crown prince met President Trump; Peru seeks to curb mercury in small-scale gold mining; UK uses AI to fast-track antibiotics; Winter Olympics entry questioned.
This AI method could turbocharge the hunt for new medicines
An AI model trained on cellular genomic perturbation data can accelerate drug discovery by predicting compound effects across cell types, reducing costly large-scale screens.
AMPLY Discovery raised $1.75M to develop innovative AI-driven drug discovery therapies targeting cancers and drug-resistant infections in preclinical stages.